学术周报 · IF≥10
胆胰外科领域文献阅读汇编
2026年第42周 (2026-10-17) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Cancer letters | 4 | IF 11.8 |
| Endoscopy | 2 | IF 11.8 |
| Cell | 2 | IF 45.1 |
| Cancer cell | 2 | IF 56.1 |
| Cancer research | 1 | IF 22.6 |
| JAMA surgery | 1 | IF 15.6 |
| eGastroenterology | 1 | IF 10.5 |
| ESMO open | 1 | IF 10.6 |
| Pharmacological research | 1 | IF 12.2 |
1胰腺癌 (8篇)
临床研究 (3篇)
In this issue of Cancer Cell, Shi et al. report encouraging early-phase results combining HRS-4642, an allele-specific KRAS G12D inhibitor, with the PD-L1 inhibitor adebrelimab in previously treated metastatic pancreatic cancer. The intravenous combination was safe and well tolerated, notably sparing patients the gastrointestinal toxicity common to oral KRAS inhibitors, and achieved a promising 43% response rate at the recommended dose.
中文摘要:本期 Cancer Cell 中,Shi 等报告了 HRS-4642(一种等位基因特异性 KRAS G12D 抑制剂)联合 PD-L1 抑制剂 adebrelimab 在既往接受过治疗的转移性胰腺癌患者中的早期临床结果,令人鼓舞。该静脉联合方案安全且耐受良好,尤其使患者免于口服 KRAS 抑制剂常见的胃肠道毒性,并在推荐剂量下达到有希望的 43% 缓解率。
KRAS G12D mutations drive approximately 40% of pancreatic ductal adenocarcinoma (PDAC) cases and foster an immunosuppressive tumor microenvironment. This phase 1/2 trial (NCT06427239) evaluated HRS-4642, a selective KRAS G12D inhibitor, combined with the PD-L1 blockade adebrelimab in 48 pretreated patients with metastatic KRAS G12D-mutant PDAC. Dose escalation revealed no dose-limiting toxicities, establishing the recommended phase 2 dose (RP2D), and no treatment-related deaths occurred; hypercholesterolemia and anemia (each 50%) were the most common treatment-related adverse events. In the RP2D cohort (n = 37), the confirmed objective response rate was 43.2% (95% confidence interval [CI], 27.1-60.5), disease control rate was 81.1% (95% CI, 64.8-92.0), median duration of response was 6.9 months (95% CI, 4.8-8.6), median progression-free survival was 5.7 months (95% CI, 4.0-7.5), and median overall survival was 11.5 months (95% CI, 9.2-16.9). This chemotherapy-free regimen is tolerable and shows encouraging antitumor activity in refractory KRAS G12D-mutant PDAC, warranting further investigation.
中文摘要:KRAS G12D突变约占胰腺导管腺癌(PDAC)病例的40%,并促进免疫抑制性肿瘤微环境。这项1/2期试验(NCT06427239)评估选择性KRAS G12D抑制剂HRS-4642联合PD-L1阻断剂adebrelimab,用于48例既往接受过治疗的转移性KRAS G12D突变PDAC患者。剂量递增阶段未观察到剂量限制性毒性,确定了2期推荐剂量(RP2D),未发生治疗相关死亡;高胆固醇血症和贫血(各占50%)是最常见的治疗相关不良事件。在RP2D队列(n=37)中,确认的客观缓解率为43.2%(95%置信区间[CI] 27.1-60.5),疾病控制率为81.1%(95% CI 64.8-92.0),中位缓解持续时间为6.9个月(95% CI 4.8-8.6),中位无进展生存期为5.7个月(95% CI 4.0-7.5),中位总生存期为11.5个月(95% CI 9.2-16.9)。这一无化疗方案耐受性可接受,在难治性KRAS G12D突变PDAC中显示出令人鼓舞的抗肿瘤活性,值得进一步研究。
To evaluate the clinical applicability of previously established transcriptomic signatures (molecular subtypes, components and GemPred status) in metastatic pancreatic cancer, we conducted a retrospective pooled analysis of 178 patients from three phase 2 trials (PRODIGE35/37, AFUGEM; 2013-2016) testing first-line regimens (FOLFIRINOX, GemNab, FuNab, FOLFIRI3). RNA sequencing was performed on primary/metastatic tumors across French centers, with blinded assessment of subtypes (immune classical, pure basal-like, stroma-activated), quantitative components, and GemPred status. Primary endpoint: progression-free survival (PFS). Immune classical subtype showed superior median PFS (9.03 months) and OS (11.27 months) versus basal-like and stroma-activated subtypes (PFS: p = 0.015; OS: p = 0.010). Higher classical component correlated with improved OS (HR = 0.737, p = 0.005) but not PFS (HR = 0.90, p = 0.339). Inactive stroma predicted better PFS (HR = 0.66, p = 0.003) and OS (HR = 0.697, p = 0.013). GemPred-negative patients treated with FOLFIRINOX versus GemNab had higher ORR (46.9% vs. 19.1%, p = 0.046), longer PFS (8.2 vs. 2.3 months; HR = 2.28, p = 0.008), and OS (11.6 vs. 5.0 months; HR = 2.04, p = 0.021). No differences occurred in GemPred-positive patients. In a formal treatment-by-GemPred interaction analysis (FOLFIRINOX vs. GemNab), the interaction was significant for OS (adjusted p-interaction = 0.050) but not for PFS (adjusted p-interaction = 0.51). Transcriptomic signatures retain prognostic and predictive utility in metastatic pancreatic cancer, with GemPred representing a hypothesis-generating predictive signal for OS (e.g., a FOLFIRINOX OS benefit in GemPred-negative). Prospective validation is warranted for clinical implementation.
中文摘要:为评估既有转录组特征(分子亚型、组分及GemPred状态)在转移性胰腺癌中的临床适用性,对3项2期试验(PRODIGE35/37、AFUGEM;2013—2016年)共178例患者进行回顾性汇总分析,这些试验检验一线方案FOLFIRINOX、GemNab、FuNab、FOLFIRI3。法国各中心对原发或转移肿瘤行RNA测序,盲法评估亚型(免疫经典型、纯基底样型、基质激活型)、定量组分及GemPred状态。主要终点为无进展生存期(PFS)。免疫经典型的中位PFS(9.03个月)和总生存期(OS,11.27个月)优于基底样型和基质激活型(PFS:p=0.015;OS:p=0.010)。经典型组分较高与OS改善相关(HR=0.737,p=0.005),但与PFS无关(HR=0.90,p=0.339)。基质失活预示更好的PFS(HR=0.66,p=0.003)和OS(HR=0.697,p=0.013)。GemPred阴性患者接受FOLFIRINOX较GemNab的客观缓解率更高(46.9% vs. 19.1%,p=0.046)、PFS更长(8.2 vs. 2.3个月;HR=2.28,p=0.008)、OS更长(11.6 vs. 5.0个月;HR=2.04,p=0.021)。GemPred阳性患者未见差异。在正式的治疗与GemPred交互作用分析中(FOLFIRINOX vs. GemNab),OS交互作用显著(校正p交互=0.050),PFS不显著(校正p交互=0.51)。转录组特征在转移性胰腺癌中保留预后和预测价值,GemPred为OS提供了可产生假设的预测信号(例如GemPred阴性者可从FOLFIRINOX获得OS获益)。临床落地仍需前瞻性验证。
基础研究 (5篇)
Sex differences in cancer therapy response remain poorly understood. Using a "phase II-like preclinical trial" across 55 CLDN18.2+ pancreatic cancer patient-derived xenografts, we identify marked female-biased resistance to CLDN18.2-targeted antibody-drug conjugate (ADC) therapy despite equivalent antigen expression. Mechanistically, estrogen signals through GPER1 to upregulate TRAF6, redirecting tumor-intrinsic STING signaling from IRF3-mediated interferon production toward nuclear factor κB (NF-κB) activation. This drives CXCL1 secretion, neutrophil recruitment, and neutrophil extracellular trap (NET) formation. NETs form a charged extracellular network that restricts antibody access to tumor-cell-surface antigens-a mechanism we term functional antigen shielding-reducing ADC cytotoxicity independently of antigen expression. The NET burden also correlated with poorer responses to trastuzumab, cetuximab, and enfortumab vedotin across three clinical cohorts. Pharmacologic NET disruption with sivelestat restored ADC efficacy in female mice. These findings reveal an estrogen-driven resistance mechanism with broad implications for antibody-based cancer therapy.
中文摘要:癌症治疗反应中的性别差异仍知之甚少。我们利用覆盖55例CLDN18.2阳性胰腺癌患者来源异种移植瘤的「II期临床试验样临床前试验」,发现尽管抗原表达相当,雌性仍对CLDN18.2靶向抗体偶联药物(ADC)治疗表现出明显抵抗。机制上,雌激素经GPER1信号上调TRAF6,使肿瘤内在STING信号由IRF3介导的干扰素产生转向核因子κB(NF-κB)激活。这促进CXCL1分泌、中性粒细胞募集及中性粒细胞胞外诱捕网(NET)形成。NET形成带电荷的细胞外网络,限制抗体接近肿瘤细胞表面抗原,我们将这一机制称为「功能性抗原屏蔽」,其在不依赖抗原表达的情况下降低ADC细胞毒性。NET负荷还与三个临床队列中对曲妥珠单抗、西妥昔单抗和恩诺单抗维多汀较差反应相关。使用西维来司他进行药理学NET破坏可恢复雌性小鼠中的ADC疗效。这些发现揭示了一种雌激素驱动的耐药机制,对基于抗体的癌症治疗具有广泛意义。
Pancreatic ductal adenocarcinoma (PDAC), an aggressive cancer with a poor prognosis, contains resident tissue macrophages (RTMs) present before tumor onset and monocyte-derived macrophages recruited during tumor development, but their distinct roles in supporting tumor progression remain unclear. Combining single-cell profiling, spatial analysis, lineage tracing, RTM depletion, and selenium tracing, we found that RTMs preferentially localize at the tumor border, where they promote epithelial-mesenchymal transition (EMT), tumor growth, and metastasis. Mechanistically, RTMs transfer the selenium transporter Selenop to EMThi tumor cells through LRP8-dependent uptake, increasing tumor-cell selenium availability, limiting lipid peroxidation, and shielding EMThi tumor cells from ferroptosis. RTM-specific Selenop deletion or tumor-cell Lrp8 disruption reduced EMT and tumor progression, whereas ferroptosis inhibition reversed the effect of RTM depletion. Human PDAC showed border-enriched SEPP1+ RTMs near EMThi tumor cells, suggesting a conserved macrophage-derived selenium niche that supports invasive tumor states and highlighting the potential for targeting RTMs or their secretory factors in PDAC.
中文摘要:胰腺导管腺癌(PDAC)侵袭性强、预后差,其中存在肿瘤发生前即存在的组织驻留巨噬细胞(RTMs)以及肿瘤发展过程中募集的单核细胞来源巨噬细胞,但二者在支持肿瘤进展中的不同作用仍不清楚。研究结合单细胞图谱、空间分析、谱系追踪、RTM清除和硒示踪,发现RTMs优先定位于肿瘤边界,促进上皮-间质转化(EMT)、肿瘤生长和转移。机制上,RTMs通过LRP8依赖的摄取将硒转运蛋白Selenop转移至EMThi肿瘤细胞,提高肿瘤细胞硒可利用性,限制脂质过氧化,使EMThi肿瘤细胞免受铁死亡。RTM特异性敲除Selenop或破坏肿瘤细胞Lrp8可减少EMT和肿瘤进展,而抑制铁死亡可逆转RTM清除的效果。人PDAC中可见靠近EMThi肿瘤细胞的边界富集SEPP1+ RTMs,提示存在支持侵袭性肿瘤状态的保守巨噬细胞来源硒微环境,并凸显靶向RTMs或其分泌因子在PDAC中的潜力。
Pancreatic ductal adenocarcinoma (PDA) is among the deadliest malignancies, driven by metastatic progression and profound cellular heterogeneity. We previously identified glutathione S-transferase theta 1 (GSTT1) as a regulator of a slow-cycling, highly metastatic tumor cell population, suggesting that GSTT1High cells may possess stem-like properties. Here, we define the functional and molecular features of this subpopulation in metastatic PDA. Using a mCherry-tagged Gstt1 reporter system in metastatic murine PDAC cells, we enriched for Gstt1High cells and observed increased tumor sphere formation, accompanied by upregulation of stemness-associated genes including PROM1 (CD133) and activation of Wnt and FGF signaling pathways. In human PDA models, CD133HighGSTT1High cells exhibited enhanced tumor sphere initiation and expansion compared to other populations, defining a maximal stem-like state. Notably, sensitivity to FGFR inhibitors was observed only under tumor sphere conditions, highlighting a context-dependent therapeutic vulnerability. Mechanistically, FGFR3 expression correlated with GSTT1 and CD133 levels, and FGF signaling was required to sustain this state. GSTT1 knockdown reduced CD133 protein levels, impaired tumor sphere formation, and altered sensitivity to FGFR inhibition. These findings were largely recapitulated in patient-derived PDA organoids, where GSTT1 and PROM1 co-expression predicted increased tumor sphere formation and enhanced response to the multi-kinase inhibitor Nintedanib. Together, these results identify a GSTT1HighCD133High stem-like subpopulation in metastatic PDA and identify an FGFR-dependent signaling axis that sustains this state, representing a potential therapeutic vulnerability.
中文摘要:胰腺导管腺癌(PDA)是最致命的恶性肿瘤之一,其进展由转移和显著的细胞异质性驱动。前期工作鉴定出谷胱甘肽S-转移酶theta 1(GSTT1)是慢周期、高转移肿瘤细胞群的调控因子,提示GSTT1High细胞可能具有干样特性。在此,我们界定该亚群在转移性PDA中的功能与分子特征。利用在转移性小鼠PDAC细胞中构建的mCherry标记Gstt1报告系统,富集Gstt1High细胞后观察到肿瘤球形成增加,并伴随包括PROM1(CD133)在内的干性相关基因上调以及Wnt和FGF信号通路激活。在人PDA模型中,CD133HighGSTT1High细胞较其他细胞群表现出更强的肿瘤球起始和扩增能力,构成一种最大程度的干样状态。对FGFR抑制剂的敏感性仅在肿瘤球条件下出现,提示一种依赖背景的治疗脆弱性。机制上,FGFR3表达与GSTT1和CD133水平相关,FGF信号是维持该状态所必需的。敲低GSTT1可降低CD133蛋白水平、削弱肿瘤球形成并改变对FGFR抑制的敏感性。上述发现在患者来源的PDA类器官中大部分得到重现,其中GSTT1与PROM1共表达可预测肿瘤球形成增加以及对多激酶抑制剂尼达尼布的反应增强。这些结果确定转移性PDA中存在GSTT1HighCD133High干样亚群,并识别出维持该状态的FGFR依赖信号轴,构成潜在治疗脆弱点。
Gemcitabine remains a cornerstone treatment for pancreatic ductal adenocarcinoma (PDAC), yet the emergence of resistance constitutes a major clinical challenge with poorly understood epigenomic mechanisms. Here, we identified the pioneer transcription factor Foxa1 as a master regulator of gemcitabine resistance through multi-omics analysis. Mechanistically, Foxa1 drives widespread super-enhancer (SE) reprogramming and 3D genome remodelling in resistant cells, which coordinately activates the expression of key resistance genes, notably Rrm1 and Cdadc1. This is accompanied by increased chromatin accessibility, elevated H3K27ac enrichment at SEs, and enhanced Foxa1 binding at regulatory elements. Moreover, post-translational stabilization of Foxa1 via USP7-mediated deubiquitination sustains this epigenomic program. Genetic ablation of Foxa1 or specific SE regions near Rrm1 resensitizes resistant cells to gemcitabine. Building upon this mechanism, we demonstrate that bromodomain and extraterminal (BET) inhibitors, which disrupt SE function, potently reverse resistance. Notably, the clinical-stage BET inhibitor AZD5153, in combination with gemcitabine, achieves robust tumor suppression and overcomes resistance in cell-derived xenograft (CDX) models by dismantling the Foxa1-mediated resistant transcriptome and reinvigorating drug sensitivity. Our findings establish Foxa1-orchestrated enhancer reprogramming as a fundamental mechanism of gemcitabine resistance and unveil a promising epigenetic therapy to restore treatment efficacy in PDAC.
中文摘要:吉西他滨仍是胰腺导管腺癌(PDAC)治疗的基石,但耐药的出现构成主要临床挑战,其表观基因组机制了解不足。本研究通过多组学分析确定先锋转录因子Foxa1是吉西他滨耐药的主调控因子。机制上,Foxa1在耐药细胞中驱动广泛的超级增强子(SE)重编程和三维基因组重塑,协同激活关键耐药基因Rrm1和Cdadc1的表达。这一过程伴随染色质可及性增加、SE处H3K27ac富集升高以及调控元件上Foxa1结合增强。USP7介导的去泛素化使Foxa1蛋白翻译后稳定,维持该表观基因组程序。敲除Foxa1或Rrm1附近特定SE区域可使耐药细胞对吉西他滨重新敏感。基于此机制,破坏SE功能的溴结构域和超末端(BET)抑制剂能有效逆转耐药。临床阶段BET抑制剂AZD5153与吉西他滨联合,在细胞来源异种移植(CDX)模型中通过瓦解Foxa1介导的耐药转录组并恢复药物敏感性,实现强效肿瘤抑制并克服耐药。这些发现确立Foxa1编排的增强子重编程是吉西他滨耐药的基本机制,并揭示一种有前景的表观遗传疗法以恢复PDAC治疗疗效。
Pancreatic ductal adenocarcinoma (PDAC) is characterized by high malignancy and poor prognosis. However, chemotherapy remains the cornerstone of its treatment. Through transcriptomic analysis of gemcitabine-treated PDAC cells, we identified TRDMT1, rather than other known 5-methylcytosine (m5C) methyltransferases, as a principal regulator of mRNA m5C methylation. TRDMT1 deficiency attenuated the malignant phenotype of PDAC cells and increased their sensitivity to gemcitabine, 5-fluorouracil, oxaliplatin, and irinotecan. Furthermore, deletion of TRDMT1 impaired the recruitment of homologous recombination-related proteins, including BRCA1, RAD51, and RAD52. Analysis of mRNA m5C modification sequencing in TRDMT1-deficient PDAC cells demonstrated that IRS2 exhibited significantly reduced m5C methylation levels and decreased expression. The IRS2/PI3K/AKT axis was identified as the potential downstream signaling pathway through which TRDMT1 mediated the chemotherapeutic response. Survival data from patients with PDAC, and findings from TRDMT1-deficient mouse models, further supported the role of TRDMT1 in reducing chemosensitivity. Collectively, these findings indicate that TRDMT1-mediated mRNA m5C methylation is essential for homologous recombination repair in PDAC and suggest that TRDMT1 may represent a potential therapeutic target for overcoming chemoresistance.
中文摘要:胰腺导管腺癌(PDAC)恶性程度高、预后差,化疗仍是其治疗基石。通过对吉西他滨处理的PDAC细胞进行转录组分析,我们发现TRDMT1而非其他已知的5-甲基胞嘧啶(m5C)甲基转移酶,是mRNA m5C甲基化的主要调控因子。TRDMT1缺失削弱PDAC细胞的恶性表型,并提高其对吉西他滨、5-氟尿嘧啶、奥沙利铂和伊立替康的敏感性。TRDMT1缺失还损害同源重组相关蛋白BRCA1、RAD51和RAD52的募集。对TRDMT1缺陷PDAC细胞的mRNA m5C修饰测序分析显示,IRS2的m5C甲基化水平显著降低且表达下降。IRS2/PI3K/AKT轴被确定为TRDMT1介导化疗反应的潜在下游信号通路。PDAC患者生存数据及TRDMT1缺陷小鼠模型结果进一步支持TRDMT1降低化疗敏感性的作用。这些发现表明,TRDMT1介导的mRNA m5C甲基化对PDAC同源重组修复至关重要,并提示TRDMT1可能成为克服化疗耐药的潜在治疗靶点。
2胆管癌/胆道手术 (3篇)
临床研究 (2篇)
Biliary tract cancers (BTCs) are associated with poor outcomes, with many patients never receiving any cancer-directed treatment. Population-based registries from England, France, Italy and Spain share a similar picture: emergency presentation, rather than planned referral, accounts for roughly half of diagnoses, and >50% of patients with cholangiocarcinoma in England received neither surgery, systemic therapy nor stenting. This attrition is not exclusive to real-world settings: in PROOF-301 and FIGHT-302, a considerable proportion of eligible or randomly assigned patients never started their allocated treatment. BTC is also no longer a disease confined to older adults, with ∼7% of cases diagnosed in individuals <50 years of age. On top of this, access to reimbursed therapies, molecular profiling and expert multidisciplinary discussion remains markedly uneven across Europe. "Our patients deserve better" and closing these gaps in diagnosis, access to treatment and care delivery is as urgent as developing new drugs for this disease.
中文摘要:胆道恶性肿瘤(BTC)预后差,许多患者从未接受任何针对肿瘤的治疗。来自英格兰、法国、意大利和西班牙的人群登记数据呈现相似图景:约半数诊断来自急诊就诊而非计划转诊;英格兰胆管癌患者中超过50%既未接受手术,也未接受系统治疗或支架置入。这种治疗流失并非真实世界所独有:在PROOF-301和FIGHT-302中,相当比例符合条件或已随机分组的患者从未开始其分配治疗。BTC也不再局限于老年人,约7%的病例诊断于50岁以下人群。欧洲各地在可报销治疗的可及性、分子检测和专家多学科讨论方面仍明显不均衡。「我们的患者理应得到更好的照护」,缩小诊断、治疗可及性和照护提供方面的差距,与为该病开发新药同样紧迫。
Accurate staging is crucial for managing cholangiocarcinoma (CCA). Endoscopic ultrasound with tissue acquisition (EUS-TA) may enhance cross-sectional imaging-based staging; however, the impact of EUS on CCA management decision-making is unclear. 6 electronic databases were searched through to 10 July 2025 for studies on EUS-TA in staging CCA cases eligible for surgical resection or liver transplantation. The primary outcome was the pooled proportion of patients excluded from curative-intent surgery based on the EUS findings, which included newly detected findings and confirmation by EUS-TA of cross-sectional imaging findings. Secondary outcomes included the pooled incremental benefit of EUS (IBEUS) over cross-sectional imaging and EUS-specific adverse events. The IBEUS was defined as the proportion of patients with malignant lymph nodes identified by EUS-TA but not by cross-sectional imaging, relative to all patients who underwent cross-sectional imaging. 9 studies with 831 patients were included. The rate of exclusion from curative-intent surgery based on EUS findings was 10% overall (95%CI 6%-18%; 9 studies), 7% for perihilar CCA (pCCA; 95%CI 2%-19%; 5 studies), 10% for those planned for resection (95%CI 4%-22%; 5 studies), and 8% for those planned for transplantation (95%CI 3%-22%; 3 studies). The pooled IBEUS was 3% (95%CI 1%-10%; 5 studies) overall, 4% (95%CI 1%-17%; 3 studies) for pCCA, 1% (95%CI 0%-3%; 2 studies) in patients intended for operative resection, and 7% (95%CI 1%-26%; 2 studies) in those intended for transplantation. EUS may impact CCA staging and support treatment decisions.
中文摘要:准确分期对胆管癌(CCA)诊疗至关重要。内镜超声联合组织获取(EUS-TA)可能增强基于横断面影像的分期;但EUS对CCA治疗决策的影响尚不清楚。检索6个电子数据库至2025年7月10日,纳入EUS-TA用于适合手术切除或肝移植的CCA病例分期的研究。主要结局为基于EUS发现而被排除于根治性手术之外的患者合并比例,EUS发现包括新发现的病变以及EUS-TA对横断面影像发现的确认。次要结局包括EUS相对横断面影像的合并增量获益(IBEUS)和EUS特异性不良事件。IBEUS定义为EUS-TA识别出恶性淋巴结而横断面影像未识别的患者比例,相对于所有接受横断面影像的患者。纳入9项研究、831例患者。基于EUS发现排除根治性手术的比例总体为10%(95%CI 6%-18%;9项研究),肝门部CCA(pCCA)为7%(95%CI 2%-19%;5项研究),计划切除者为10%(95%CI 4%-22%;5项研究),计划移植者为8%(95%CI 3%-22%;3项研究)。合并IBEUS总体为3%(95%CI 1%-10%;5项研究),pCCA为4%(95%CI 1%-17%;3项研究),拟行手术切除者为1%(95%CI 0%-3%;2项研究),拟行移植者为7%(95%CI 1%-26%;2项研究)。EUS可能影响CCA分期并支持治疗决策。
基础研究 (1篇)
Intrahepatic cholangiocarcinoma (ICC) is a lethal hepatic malignancy characterized by a prominent desmoplastic stroma. In this study, we demonstrated that AT-rich interactive domain-containing protein 1A (ARID1A), a core component of the Switch/Sucrose (SWI/SNF) protein complex, is upregulated in ICC and plays an oncogenic role. Mechanistically, ARID1A stabilized NICD1 protein by inhibiting AMPK-dependent autophagy and lysosomal degradation, thereby sustaining Notch signaling. Tolloid-like 1 (TLL1), a metalloproteinase that promotes collagen maturation, was found to be a downstream effector of ARID1A/Notch signaling. Specifically, TLL1 derived from ICC cells activated hepatic stellate cells (HSC) and thus promoted tumor progression. Accordingly, ablation of TLL1 attenuated cancer-associated fibroblast infiltration, collagen accumulation, and tumor progression. Moreover, virtual screening of a bioactive compound library identified acarbose, an effective medicine for glycemic control, as a potent inhibitor of TLL1. Pharmacologic inhibition of TLL1 with acarbose suppressed HSC activation, collagen deposition, and tumor development. Collectively, these results establish a tumor-promoting ARID1A-Notch-TLL1 axis in ICC and reveal acarbose as a potential precision therapy for patients with ARID1A-high ICC. The ARID1A-Notch-TLL1 axis promotes hepatic stellate cell activation and intrahepatic cholangiocarcinoma development, which can be targeted with acarbose as a TLL1 inhibitor to suppress tumor progression.
中文摘要:肝内胆管癌(ICC)是一种致死性肝脏恶性肿瘤,以显著的促结缔组织增生性间质为特征。本研究发现,Switch/Sucrose(SWI/SNF)蛋白复合物核心组分AT-rich interactive domain-containing protein 1A(ARID1A)在ICC中上调并发挥致癌作用。机制上,ARID1A通过抑制AMPK依赖性自噬和溶酶体降解稳定NICD1蛋白,从而维持Notch信号。促进胶原成熟的金属蛋白酶Tolloid-like 1(TLL1)被确定为ARID1A/Notch信号的下游效应分子。ICC细胞来源的TLL1可激活肝星状细胞(HSC),进而促进肿瘤进展。敲除TLL1可减轻癌相关成纤维细胞浸润、胶原蓄积和肿瘤进展。对生物活性化合物库进行虚拟筛选发现,血糖控制有效药物阿卡波糖是TLL1的有效抑制剂。用阿卡波糖药理学抑制TLL1可抑制HSC活化、胶原沉积和肿瘤发展。这些结果确立了ICC中促进肿瘤的ARID1A-Notch-TLL1轴,并提示阿卡波糖可作为ARID1A高表达ICC患者的潜在精准治疗。ARID1A-Notch-TLL1轴促进肝星状细胞活化和肝内胆管癌发展,可通过阿卡波糖作为TLL1抑制剂靶向该轴以抑制肿瘤进展。
3术后并发症/胰瘘 (1篇)
临床研究 (1篇)
Endoscopic ultrasound (EUS)-guided drainage is increasingly used for the management of postoperative pancreatic fluid collections (POPFC). We aimed to identify factors associated with clinical success, and to perform exploratory analyses of outcomes stratified by surgery type and stent type. We performed a retrospective multicenter cohort study including patients who underwent EUS-guided drainage of POPFC following pancreatic surgery between 2014 and August 2024 at three academic centers. The primary outcome was clinical success, defined as combined radiological and clinical resolution without the need for percutaneous or surgical step-up intervention. A total of 265 patients were included (mean age 64±14 years; 57% male; 52% underwent drainage ≤14 days after surgery, necrotic component in 51%). Clinical success was achieved in 194 patients (73%; 95% CI 67.5-78.1%), including 160 (60%; 95% CI 54.5-66.3%) after a single procedure and 34 after additional endoscopic reinterventions, while 20 patients (7.6%; 95% CI 4.4-10.7%) required percutaneous or surgical step-up. Distal pancreatectomy, compared with pancreaticoduodenectomy, was associated with a higher rate of reintervention (32% vs. 20%, p=0.02) and independently associated with lower odds of clinical success (odds ratio 0.53, 95% confidence interval 0.29-0.98; p=0.04). EUS-guided drainage for POPFC appears effective, with an acceptable safety profile in expert centers, achieving clinical resolution in the majority of patients. Distal pancreatectomy was associated with a more complex treatment course. These findings support the use of EUS-guided drainage as a central component in the management of POPFC.
中文摘要:内镜超声引导下引流越来越多用于术后胰腺液体积聚(POPFC)的处理。研究旨在识别与临床成功相关的因素,并按手术类型和支架类型对结局做探索性分析。该回顾性多中心队列研究纳入2014年至2024年8月在三家学术中心因胰腺手术后POPFC接受内镜超声引导下引流的患者。主要结局为临床成功,定义为影像学和临床共同缓解,且无需经皮或手术升级干预。共纳入265例患者,平均年龄64±14岁,男性57%,52%在术后14天内接受引流,51%存在坏死成分。194例(73%;95%CI 67.5-78.1%)获得临床成功,其中160例(60%;95%CI 54.5-66.3%)在单次操作后成功,34例在额外内镜再干预后成功;20例(7.6%;95%CI 4.4-10.7%)需要经皮或手术升级干预。与胰十二指肠切除相比,远端胰腺切除与更高的再干预率相关(32%对20%,p=0.02),并与临床成功几率降低独立相关(OR 0.53,95%CI 0.29-0.98;p=0.04)。在专家中心,内镜超声引导下引流治疗POPFC有效且安全性可接受,多数患者获得临床缓解。远端胰腺切除与更复杂的治疗过程相关。这些结果支持将内镜超声引导下引流作为POPFC管理的核心组成部分。
4减重手术 (1篇)
临床研究 (1篇)
Obesity is associated with elevated risks for multiple cancers. How bariatric surgery influences these risks across age and sex is insufficiently understood. To evaluate the association between bariatric surgery and obesity-related cancer (breast, endometrial, ovarian, esophageal adenocarcinoma, liver, pancreatic, colon, rectal, kidney, and multiple myeloma) and whether this association varies by age and sex. This population-based cohort study within the Nordic Obesity Surgery Cohort (NordOSCo) included individuals aged 18 to 59 years with an obesity record in Denmark, Finland, or Sweden from 1992 to 2023. Prospectively collected data on exposure, outcomes, and confounders were obtained from well-maintained national registries. Follow-up continued until cancer diagnosis, death, emigration, or December 31, 2023. These data were analyzed from December 2025 to April 2026. Bariatric surgery vs no surgery among individuals with obesity. The primary outcome was incidence of obesity-related cancers. Risks were compared using crude and multivariable-adjusted incidence rate ratios (aIRR) with 95% CIs derived from Poisson regression adjusted for age, sex, calendar year, country, and obesity- and lifestyle-related comorbidities. Effect modification by age group (18-39 vs 40-59 years) and sex (female vs male) was evaluated using interaction terms. Among 784 105 individuals with obesity (569 266 women [73%] and 214 839 men [27%]), 99 614 underwent bariatric surgery. Surgery was associated with a lower risk of obesity-related cancer overall (aIRR, 0.81; 95% CI, 0.77-0.85). The magnitude of risk reduction did not differ by age group (individuals aged 18 to 39 years: aIRR, 0.80; 95% CI, 0.72-0.88 and individuals aged 40 to 59 years: aIRR, 0.81; 95% CI, 0.78-0.86) (P for interaction = .88). Associations for non-sex-specific cancers were similar in men and women (P for interaction = .50). For individual cancers, the strongest inverse associations were observed for liver cancer (aIRR, 0.49; 95% CI, 0.34-0.70), endometrial cancer (aIRR, 0.51; 95% CI, 0.45-0.59), and ovarian cancer (aIRR, 0.73; 95% CI, 0.60-0.87). In contrast, pancreatic cancer risk was increased after surgery, particularly among younger adults (aIRR, 2.21; 95% CI, 1.44-3.39; P = .01). In this study, bariatric surgery was associated with a lower long-term risk of obesity-related cancers, with similar associations across age groups and sexes. These findings suggest that the long-term oncologic benefits of bariatric surgery apply broadly across age groups and sexes, supporting equitable access to bariatric surgery for patients with obesity.
中文摘要:肥胖与多种癌症风险升高相关。减重手术如何在不同年龄和性别中影响这些风险,尚缺乏充分认识。评估减重手术与肥胖相关癌症(乳腺癌、子宫内膜癌、卵巢癌、食管腺癌、肝癌、胰腺癌、结肠癌、直肠癌、肾癌和多发性骨髓瘤)之间的关联,以及该关联是否随年龄和性别而变化。这项基于人群的队列研究纳入北欧肥胖手术队列(NordOSCo)中1992年至2023年在丹麦、芬兰或瑞典有肥胖记录的18至59岁个体。暴露、结局和混杂因素数据来自维护良好的国家登记系统,为前瞻性收集。随访持续至癌症诊断、死亡、移民或2023年12月31日。数据于2025年12月至2026年4月分析。比较肥胖个体中接受减重手术与未接受手术者。主要结局为肥胖相关癌症的发病率。采用泊松回归计算粗率和多变量校正发病率比(aIRR)及95% CI,校正年龄、性别、日历年、国家以及肥胖和生活方式相关合并症。通过交互项评估年龄组(18-39岁与40-59岁)和性别(女性与男性)的效应修饰。在784 105名肥胖个体(569 266名女性[73%]和214 839名男性[27%])中,99 614人接受减重手术。手术与肥胖相关癌症总体风险降低相关(aIRR,0.81;95% CI,0.77-0.85)。风险降低幅度在年龄组间无差异(18至39岁:aIRR,0.80;95% CI,0.72-0.88;40至59岁:aIRR,0.81;95% CI,0.78-0.86)(交互作用P=.88)。非性别特异性癌症的关联在男性和女性中相似(交互作用P=.50)。就单个癌症而言,最强的负向关联见于肝癌(aIRR,0.49;95% CI,0.34-0.70)、子宫内膜癌(aIRR,0.51;95% CI,0.45-0.59)和卵巢癌(aIRR,0.73;95% CI,0.60-0.87)。相反,手术后胰腺癌风险升高,尤其在较年轻成人中(aIRR,2.21;95% CI,1.44-3.39;P=.01)。在这项研究中,减重手术与肥胖相关癌症的长期风险降低相关,且不同年龄组和性别间的关联相似。这些发现提示减重手术的长期肿瘤学获益广泛适用于不同年龄组和性别,支持肥胖患者公平获得减重手术。
5肝切除/肝癌手术 (1篇)
临床研究 (1篇)
Imaging features play a central role in hepatocellular carcinoma (HCC) staging, but current systems remain limited in prognostic precision and treatment guidance. Pathological gross classification, which categorises HCC into four subtypes based on tumour margin morphology, represents a morphological surrogate of aggressive tumour behaviour encompassing histological and molecular features and has demonstrated value in predicting prognosis and guiding adjuvant locoregional therapy selection. Importantly, gross classification is assessable through imaging, but its evaluation utterly depends on postoperative pathology and remains subjective, time-consuming and poorly reproducible. We aimed to develop a three-dimensional (3D) Foundation Model-driven system to automatically perform non-invasive morphological phenotyping and to evaluate its prognostic utility. A cohort of 551 patients who underwent hepatectomy after gadoxetic acid-enhanced MRI from two medical centres was retrospectively analysed. Pathological gross classification served as the reference standard. The 3D MorphStratify Model was built to automatically phenotype 3D gross classification with a dedicated 3D Foundation Model encoder and a channel-aware fusion module. A combined model integrating 3D MorphStratify and Conventional Imaging Predictors (Morph-CIP) was constructed and validated for recurrence risk stratification. The biological rationale linking imaging morphological phenotyping to underlying biology was preliminarily explored. Eligible patients were divided into a development dataset (n=291), a validation dataset (n=192) and an external test set (n=68). The 3D MorphStratify Model achieved a micro-averaged area under the receiver operating characteristic curve (AUC) of 0.932, significantly outperforming senior radiologists (AUC 0.825) with about 40-fold improved efficiency. The imaging-based 3D morphological phenotyping (3D MorphStratify) independently predicted poor recurrence-free survival (RFS, HR 2.16, 95% CI 1.20 to 3.87, p=0.010). The Morph-CIP Model enables risk stratification through training set (AUC 0.836, 0.768, 0.765 for 1-year, 2-year, 3-year RFS), internal test set (AUC 0.816, 0.690, 0.711) and external test set (AUC 0.737, 0.709, 0.702). The high-risk group is characterised by the enrichment of glycolysis and hypoxia signalling pathways. 3D MorphStratify is the first automated 3D morphological phenotyping system for HCC, transforming subjective pathological gross classification into an objective, non-invasive imaging biomarker. The integration of 3D MorphStratify with conventional imaging predictors enables recurrence risk stratification, potentially providing complementary information for prognostic evaluation.
中文摘要:影像学特征在肝细胞癌(HCC)分期中居于核心位置,但现有体系在预后判断精度与治疗指导方面仍有限。病理大体分型依据肿瘤边缘形态将HCC分为四种亚型,是侵袭性肿瘤行为的形态学替代指标,涵盖了组织学与分子层面特征,在预测预后和指导辅助局部区域治疗选择方面已显示价值。大体分型可通过影像评估,但其判定完全依赖术后病理,主观性强、耗时且可重复性差。本研究旨在构建三维(3D)基础模型驱动的系统,自动完成无创形态学分型并评价其预后效用。回顾性分析两个医疗中心551例接受钆塞酸增强MRI后行肝切除术的患者,以病理大体分型为参考标准。构建3D MorphStratify模型,采用专用3D基础模型编码器和通道感知融合模块,自动对3D大体分型进行表型判定;进一步构建整合3D MorphStratify与常规影像预测因子的联合模型(Morph-CIP),并验证其复发风险分层能力;初步探讨影像形态学分型与底层生物学之间的关联依据。合格患者分为开发集(n=291)、验证集(n=192)和外部测试集(n=68)。3D MorphStratify模型的微平均受试者工作特征曲线下面积(AUC)为0.932,显著优于高年资放射科医师(AUC 0.825),效率提高约40倍。基于影像的3D形态学分型(3D MorphStratify)可独立预测较差的無复发生存(RFS,HR 2.16,95% CI 1.20至3.87,p=0.010)。Morph-CIP模型在训练集(1年、2年、3年RFS的AUC分别为0.836、0.768、0.765)、内部测试集(AUC 0.816、0.690、0.711)和外部测试集(AUC 0.737、0.709、0.702)中实现风险分层。高危组以糖酵解和缺氧信号通路富集为特征。3D MorphStratify是首个针对HCC的自动化3D形态学分型系统,将主观的病理大体分型转化为客观、无创的影像生物标志物。3D MorphStratify与常规影像预测因子的整合可实现复发风险分层,有望为预后评估提供补充信息。
6胰腺癌外科 (1篇)
基础研究 (1篇)
RAS proteins (HRAS, KRAS, NRAS) contribute to many physiological signal transduction pathways involving cell growth, cell division, and survival. RAS proteins possess GTPase activity. These proteins toggle between inactive and active forms; the conversion of inactive RAS-GDP to active RAS-GTP is facilitated by guanine nucleotide exchange factors (GEFs) turning the switch on and the intrinsic RAS-GTPase activity accelerated by the GTPase activating proteins (GAPs) turning the switch off. RAS is the upstream component of the RAS-RAF-MEK-ERK and the PI3-kinase-AKT signaling cascades. One-fifth of all cancers bear RAS mutations and about 75% of them involve KRAS. Except for the GTP/GDP binding site, RAS proteins lack deep surface pockets able to bind high-affinity inhibitors, which impeded the development of specific antagonists. KRAS mutations occur frequently in pancreatic, lung, and colorectal cancers, which are among the deadliest cancers worldwide. RAS mutations include those of codon 12 G12D/V/C/R, codon 13 G13D, and codon 61 Q61R/K/L. Studies conducted over the last 15 years led to the discovery of the so-called RAS switch II pocket. Sotorasib and adagrasib, which interact with this pocket and directly block the action of KRAS following the covalent modification of KRAS C12, are FDA-approved for the second-line treatment of KRASG12C-mutant non-small cell lung cancer. Daraxonrasib, which is an indirect inhibitor of wildtype and mutant H/K/NRAS isoforms, is FDA approved for the second-line treatment of all RAS-mutant pancreatic cancers. Daraxonrasib first forms a complex with cyclophilin A (a chaperone protein), which then interacts with active RAS to block RAS signaling.
中文摘要:RAS蛋白(HRAS、KRAS、NRAS)参与多种涉及细胞生长、细胞分裂和存活的生理信号转导通路。RAS蛋白具有GTP酶活性。这些蛋白在失活与激活形式之间切换;鸟嘌呤核苷酸交换因子(GEFs)促进失活型RAS-GDP转化为激活型RAS-GTP,使开关打开,而GTP酶激活蛋白(GAPs)加速RAS固有的GTP酶活性,使开关关闭。RAS是RAS-RAF-MEK-ERK和PI3-激酶-AKT信号级联的上游组分。全部癌症中有五分之一携带RAS突变,其中约75%涉及KRAS。除GTP/GDP结合位点外,RAS蛋白缺乏能够结合高亲和力抑制剂的深表面口袋,这阻碍了特异性拮抗剂的开发。KRAS突变常见于胰腺癌、肺癌和结直肠癌,这些癌症属于全球最致命的癌症。RAS突变包括第12位密码子G12D/V/C/R、第13位密码子G13D和第61位密码子Q61R/K/L。过去15年的研究发现了所谓的RAS开关II口袋。Sotorasib和adagrasib与该口袋相互作用,并在KRAS C12共价修饰后直接阻断KRAS作用,已获FDA批准用于KRASG12C突变非小细胞肺癌的二线治疗。Daraxonrasib是野生型和突变型H/K/NRAS亚型的间接抑制剂,已获FDA批准用于所有RAS突变胰腺癌的二线治疗。Daraxonrasib先与亲环素A(一种伴侣蛋白)形成复合物,该复合物随后与活性RAS相互作用以阻断RAS信号传导。